论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
康替固体治疗复杂腹腔感染的疗效观察
Authors Zhao Y, Xin X, Wang B, He L, Zhao Q, Ren W
Received 22 February 2024
Accepted for publication 17 July 2024
Published 5 August 2024 Volume 2024:17 Pages 3343—3351
DOI https://doi.org/10.2147/IDR.S460299
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Yongsheng Zhao,* Xianlei Xin,* Bin Wang, Lei He, Qinghua Zhao, Weizheng Ren
Faculty of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weizheng Ren; Qinghua Zhao, Faculty of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People’s Republic of China, Email rwz301@163.com; zhaoqinghuabj@163.com
Purpose: In this paper, we observed the use of contezolid in patients with complex intra-abdominal infections in the intensive care unit of the Hepatobiliary Surgery department at the Chinese PLA General Hospital.
Patients and Methods: The study collected data on complex intra-abdominal infections patients who received the antibiotic contezolid between January 2022 and April 2023.
Results: Contezolid was administered to 12 patients, including 8 with severe acute pancreatitis, 3 with intra-abdominal infections following abdominal surgery, and 1 with complicated intra-abdominal infection after trauma. Gram-positive bacteria, such as Enterococcus faecium, Enterococcus casseliflavus, Staphylococcus capitis, and Staphylococcus haemo-lytica, were detected in 11 patients. All patients who received contezolid had previously been treated with other anti-Gram-positive agents, including linezolid for 9 patients, teicoplanin for 6 patients, and vancomycin for 3 patients. The treatment with contezolid began 20.0 (15.0, 34.5) days after admission and lasted for 8.0 (6.0, 10.0) days. At the end of the treatment, the patients’ body temperature showed a significant decrease. After concomitant therapy, IL-6 levels decreased, and platelet count increased.
Conclusion: Contezolid has shown potential in treating complex intra-abdominal infections caused by Gram-positive bacteria by reducing fever and inflammatory response.
Keywords: intra-abdominal infection, contezolid, multiple drug-resistant bacteria, gram-positive bacteria